Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Twitter summary: JAMA study shows that metformin is safest first-line therapy for type 2 diabetes – future GRADE study to show best second-line therapy The journal JAMA...
Current trial results show that obese patients using Contrave are about 41% less likely to experience any major heart event (e.g. heart attack, strokes, or heart-related...
After the rapid-acting inhaled insulin Afrezza launched this February, we have been very eager to learn more about how this new product impacts patients’ day-to-day...
ClinicalTrials.gov Identifier: NCT00920582 This study is currently recruiting patients recently diagnosed with type 1 diabetes to investigate the efficacy of teplizumab...
Submitted to the FDA and could be approved this year.
$300 million and counting – how much have we learned from the heart safety trials of Onglyza and Nesina?
Twitter Summary: Lilly’s Trulicity, a once-weekly GLP-1 agonist available in US, has now been approved in Europe On November 25, Eli Lilly’s Trulicity (dulaglutide) was...
When could it reach patients?
How a new trial is testing a novel pill for blood glucose management – currently enrolling!
Twitter summary: FDA approves Novo Nordisk’s chronic weight management drug Saxenda, another option to help treat #obesity On December 23, the FDA approved Novo Nordisk’...
Complete with a savings card, a patient coaching program, and more!
How fast are insulin prices actually rising? Why might this be happening, and what is the impact on patients with varying levels of health care coverage?
Our deep dive on a new therapy now available in Europe – the benefits, risks, and when it might come to the US.
A clinical trial takes a new approach to type 1 prevention research.
The symptoms, who is at risk, and what every patient on SGLT-2 inhibitors can do right now.
What happens when these two unique drugs are taken together?
How a single change at the FDA could lead to major improvements for patients and the healthcare system.
Lilly announced that the FDA has approved its Humalog 200 units/mL KwikPen (insulin lispro) for type 1 and type 2 diabetes, making it the first concentrated mealtime...
Sanofi and MannKind announce Afrezza's official US launch.
How these two FDA-submitted drugs could address this major healthcare need.

Pages